AUG 12, 2026 · PHASE 1/2 TRIAL
A Study to Evaluate ALN-2232 in Participants With Obesity
ClinicalTrials.gov
This is a Phase 1/2 registry record for a planned interventional study with no results reported; enrollment is ongoing and no efficacy or safety data are available.
Reported
Estimated enrollment156
Study phasePhase 1, Phase 2
Primary outcome measure (Part A)Frequency of Adverse Events, up to 12 months